BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 17822748)

  • 1. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
    Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
    Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
    Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
    Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
    Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eleven years: the long and winding road.
    Ramondetta LM; Jhingran A
    Gynecol Oncol; 2007 Nov; 107(2):166-8. PubMed ID: 17950382
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Homesley HD; Filiaci V; Markman M; Bitterman P; Eaton L; Kilgore LC; Monk BJ; Ueland FR;
    J Clin Oncol; 2007 Feb; 25(5):526-31. PubMed ID: 17290061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
    Einstein MH; Klobocista M; Hou JY; Lee S; Mutyala S; Mehta K; Reimers LL; Kuo DY; Huang GS; Goldberg GL
    Gynecol Oncol; 2012 Jan; 124(1):26-30. PubMed ID: 22055846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
    Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
    Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
    Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
    Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-stage carcinosarcoma of the uterus: the significance of lymph node count.
    Temkin SM; Hellmann M; Lee YC; Abulafia O
    Int J Gynecol Cancer; 2007; 17(1):215-9. PubMed ID: 17291256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
    Galaal K; van der Heijden E; Godfrey K; Naik R; Kucukmetin A; Bryant A; Das N; Lopes AD
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD006812. PubMed ID: 23450572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
    Galaal K; Godfrey K; Naik R; Kucukmetin A; Bryant A
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006812. PubMed ID: 21249682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
    Abu-Khalaf MM; Raza MA; Hatzis C; Wang H; Lin K; Higgins S; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Santin AD; Schwartz PE
    Eur J Gynaecol Oncol; 2016; 37(2):199-203. PubMed ID: 27172745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
    Lorusso D; Martinelli F; Mancini M; Sarno I; Ditto A; Raspagliesi F
    Int J Gynecol Cancer; 2014 Sep; 24(7):1256-61. PubMed ID: 25078338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
    Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
    Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
    Randall ME; Filiaci VL; Muss H; Spirtos NM; Mannel RS; Fowler J; Thigpen JT; Benda JA;
    J Clin Oncol; 2006 Jan; 24(1):36-44. PubMed ID: 16330675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinosarcoma of the ovary-a case series.
    Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS
    Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus.
    Wong L; See HT; Khoo-Tan HS; Low JS; Ng WT; Low JJ
    Int J Gynecol Cancer; 2006; 16(3):1364-9. PubMed ID: 16803531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Uterine carcinosarcoma].
    Serkies K; Jassem J
    Ginekol Pol; 2012 Aug; 83(8):609-12. PubMed ID: 23342885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
    Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit.
    Otsuki A; Watanabe Y; Nomura H; Futagami M; Yokoyama Y; Shibata K; Kamoi S; Arakawa A; Nishiyama H; Katsuta T; Kudaka W; Shimada M; Sato N; Kotera K; Katabuchi H; Yaegashi N
    Int J Gynecol Cancer; 2015 Jan; 25(1):92-7. PubMed ID: 25347097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.